Research analysts at StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Free Report) in a research report issued to clients and investors on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.
Nabriva Therapeutics Stock Performance
The company has a quick ratio of 0.52, a current ratio of 0.85 and a debt-to-equity ratio of 0.12. Nabriva Therapeutics has a twelve month low of $1.22 and a twelve month high of $8.45. The company has a market capitalization of $45.46 million, a P/E ratio of -0.07 and a beta of 1.53.
Nabriva Therapeutics Company Profile
Further Reading
- Five stocks we like better than Nabriva Therapeutics
- ESG Stocks, What Investors Should Know
- Should You Invest in Treasury Bills?
- Investing in Commodities: What Are They? How to Invest in Them
- Analysts Think There’s Still Time to Get in on Edgewise, Up 332%
- How is Compound Interest Calculated?
- 3 Stocks Raising Dividends 4X Higher Than Inflation
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.